Invivoscribe is a global leader in precision oncology diagnostics, dedicated to improving lives with standardized molecular testing solutions. For over 30 years, the company has pioneered the international standardization of molecular and flow cytometry testing, expanding access to advanced cancer therapies worldwide. Invivoscribe develops and manufactures a comprehensive portfolio of molecular assays, reagents, controls, and bioinformatics tools under ISO 13485 design control, supporting more than 700 clinical laboratories in over 160 countries.
The company's Streamlined CDx (companion diagnostic) model accelerates the development of novel therapeutics, enabling personalized approaches to patient care. Invivoscribe's products consistently surpass industry and regulatory standards, playing a crucial role in identifying, stratifying, and monitoring hematologic cancers. Through its subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), Invivoscribe offers extensive clinical diagnostic and biopharma services, providing globally standardized flow cytometry and molecular testing services for pharmaceutical and healthcare organizations across the U.S., Europe, and Asia.
